Breaking News, Financial News

Financial Report: Alexion

Solaris revenue up 67% in the quarter

Alexion
 
1Q Revenues: $566.6 million (+67%)

1Q Earnings: $159.4 million (+94%)

Comments: Solaris sales were $566.6 million, up 67%, which included $87.8 million in reimbursements of prior year shipments related to an agreement with the French government. Sales also include additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). R&D expenses were $191.5 million, up from $74.5 in 1Q13.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters